TCT-809 Comparison of Symplicity Flex(tm), Multi-Electrode Prototype and the Symplicity Spyral(tm) Renal Denervation Catheters in a Porcine Model

Renal denervation after the symplicity HTN-3 trial

Renal denervation (RDN) by radiofrequency ablation is a minimally invasive catheter-based technique targeting the renal sympathetic nerves which has emerged as a promising therapy for resistant hypertension since the initial Symplicity HTN-1 study was published in 2009 [1]. At the time, the role of sympathetic renal nerves in the development and course of hypertension had already been proven [2...

Renal denervation for resistant hypertension-the Symplicity HTN-1 study.

Renal Denervation after Symplicity HTN-3: An Update

After three years of excessive confidence, overoptimistic expectations and performance of 15 to 20,000 renal denervation procedures in Europe, the failure of a single well-designed US trial--Symplicity HTN-3--to meet its primary efficacy endpoint has cast doubt on renal denervation as a whole. The use of a sound methodology, including randomisation and blinded endpoint assessment was enough to ...

Renal denervation for resistant hypertension—the Symplicity HTN-1 study

1884 www.thelancet.com Vol 383 May 31, 2014 blood pressure and that all further trials were being suspended, The Lancet should see fit to publish the result of the Symplicity HTN-1 trial and a largely laudatory commentary on renal denervation. When Henry Krum and colleagues published early data claiming effi cacy for renal denervation in The Lancet in 2009, I asked: “How was an otherwise well d...

Resistant hypertension and renal denervation. Considerations on the results of the SYMPLICITY HTN-3 trial.

Resistant hypertension is undoubtedly a real clinical challenge, given that it increases cardiovascular events and has no effective treatment. Thus, it is easy to see why renal sympathetic denervation (RDN) has raised expectations among physicians treating patients with this serious disease. The SYMPLICITY HTN-1 trial was a proof-of-principle trial followed by the SYMPLICITY HTN-2 trial, which ...